Proteins and Peptides
23 October 2017
US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes19 October 2017
Semaglutide receives positive 16-0 vote in favour of approval from FDA Advisory Committee18 October 2017
BioLineRx Announces Initiation of Phase 1b/2 Trial for BL-8040 in Gastric Cancer Under Immunotherapy Collaboration18 October 2017
Revance Completes Patient Enrollment in Phase 2 Program for RT002 Injectable in the Management of Plantar Fasciitis16 October 2017
Halozyme Initiates Clinical Trial Of PEGPH20 With Anti-PDL1 Immunotherapy In Cholangiocarcinoma And Gallbladder Cancer Patients13 October 2017
Prometic Announces FDA Acceptance of its Biologics License Application for Plasminogen (Ryplazim™)12 October 2017
First patient dosed in phase 1 clinical study of Molecular Partners’ second proprietary oncology asset MP027411 October 2017
Generon Receives Special Protocol Assessment for Global Phase 3 Trial of F-627 in Chemotherapy-Induced Neutropenia10 October 2017
Medicenna Presents Clinical Data on Initial Experience from Ongoing Phase 2b Study of MDNA5510 October 2017
ERYTECH Announces Resubmission of European Marketing Authorization Application for GRASPA in Acute Lymphoblastic Leukemia30 September 2017
CHMP endorses Tresiba® label update in the EU – new label reflects significant reduction in the risk of severe hypoglycaemia28 September 2017
AzurRx BioPharma and Mayoly-Spindler Announce Positive MS1819-SD Phase II Data in Exocrine Pancreatic Insufficiency (EPI)28 September 2017
Protagenic’s Neuropeptide Shows Strong Efficacy in Treating Depression and Anxiety of Established Rodent Models28 September 2017
Intarcia Provides Corporate Update22 September 2017
Versartis Announces Phase 3 VELOCITY Trial of Somavaratan in Pediatric Growth Hormone Deficiency Did Not Meet Primary Endpoint21 September 2017
Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports